The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Open accessAbstract
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years and a 5-year survival of only ∼25% [2–4]. Some more recent series seem to indicate an improvement in median overall survival [5, 6].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Interventions for fatigue and weight loss in adults with advanced progressive illness
Payne, C., Wiffen, P. J., & Martin, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008427.pub2 · Cited by 151
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationWright, A. A. (2008) · JAMA · doi:10.1001/jama.300.14.1665 · Cited by 2,788
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Self-citationRibociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationMONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationLoren, A. W., Mangu, P. B., Beck, L. N., Brennan, L., Magdalinski, A. J., Partridge, A. H., Quinn, G., Wallace, W. H., & Oktay, K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2678 · Cited by 1,611
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Self-citationWolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0902-sa · Cited by 1,474
Knaul, F. M., Farmer, P. E., Krakauer, E. L., De Lima, L., Bhadelia, A., Jiang Kwete, X., Arreola-Ornelas, H., Gómez-Dantés, O., Rodriguez, N. M., Alleyne, G. A. O., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32513-8 · Cited by 1,456
Relationship between cancer patients' predictions of prognosis and their treatment preferences
Weeks, J. C. (1998) · JAMA · doi:10.1001/jama.279.21.1709 · Cited by 1,319
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citationGrading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094 · cited 1×
“5 months) in a heavily pretreated population of ABC patients [51].”
Self-citationDelivering High-Quality Cancer Care: Charting a New Course for a System in Crisis
Levit, L. A., Balogh, E. P., Nass, S. J., & Ganz, P. A. (2014) · Cited by 1,040
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006 · cited 15×
“1 A Voters: 44 Yes: 84% (37) Abstain: 7% (3) The combination of a nonsteroidal AI and fulvestrant as first-line therapy for postmenopausal patients resulted in significant improvement in both PFS and OS compared to AI alone in one phase III trial and no benefit in a second trial with a similar design.”
InfluentialSelf-citationMerker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy152 · Cited by 954
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
Self-citationInformation needs of patients with cancer: results from a large study in UK cancer centres
Jenkins, V, Fallowfield, L., & Saul, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1573 · Cited by 845
Self-citationKaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Self-citationCherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · cited 11×
“For this reason, the MCBS for the use of palbociclib in 1st line was calculated using the PALOMA 1 trial efficacy data, which scores a 3 for efficacy.”
InfluentialSelf-citationMack, J. W., Weeks, J. C., Wright, A. A., Block, S. D., & Prigerson, H. G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4672 · Cited by 806
Peccatori, F. A., Azim, H. A., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V., & Pentheroudakis, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt199 · Cited by 790
Self-citationGucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Self-citationGreenberg, P. A., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., & Buzdar, A. U. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2197 · Cited by 738
Levin, V. A., Bidaut, L., Hou, P., Kumar, A. J., Wefel, J. S., Bekele, B. N., Prabhu, S., Loghin, M., Gilbert, M. R., & Jackson, E. F. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.061 · Cited by 729
Krop, I. E., Kim, S.-B., González-Martín, A., LoRusso, P. M., Ferrero, J.-M., Smitt, M., Yu, R., Leung, A. C. F., & Wildiers, H. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70178-0 · Cited by 724
Self-citationPlasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722 · cited 1×
“Possible reasons may include ER loss [39] or ERmutations [40].”
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
Self-citationESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Self-citationLe Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Badwe, R., Hawaldar, R., Nair, N., Kaushik, R., Parmar, V., Siddique, S., Budrukkar, A., Mittra, I., & Gupta, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00135-7 · Cited by 592
Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis
Hagerty, R. G., Butow, P. N., Ellis, P. M., Lobb, E. A., Pendlebury, S. C., Leighl, N., Mac Leod, C., & Tattersall, M. H. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.138 · Cited by 582
Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 582
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574 · cited 2×
“This combination has shown a PFS benefit of 6 months, without a significant OS benefit, and with significant toxicity [44, 45].”
Self-citationRoila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., Clark-Snow, R. A., Dupuis, L. L., Einhorn, L. H., Feyer, P., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw270 · Cited by 574
Self-citationMack, J. W., Cronin, A., Keating, N. L., Taback, N., Huskamp, H. A., Malin, J. L., Earle, C. C., & Weeks, J. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.6055 · Cited by 560
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540 · cited 6×
“Visceral crisis and endocrine resistance have been defined during ABC 2 and published [1].”
InfluentialSelf-citationEnzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Self-citationCommunicating prognosis in cancer care: a systematic review of the literature
Hagerty, R. G., Butow, P. N., Ellis, P. M., Dimitry, S., & Tattersall, M. H. N. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi211 · Cited by 504
Truth may hurt but deceit hurts more: communication in palliative care
Fallowfield, L. J., Jenkins, V. A., & Beveridge, H. A. (2002) · Palliative Medicine · doi:10.1191/0269216302pm575oa · Cited by 498
Self-citationChia, S. K., Speers, C. H., D'yachkova, Y., Kang, A., Malfair‐Taylor, S., Barnett, J., Coldman, A., Gelmon, K. A., O'Reilly, S. E., & Olivotto, I. A. (2007) · Cancer · doi:10.1002/cncr.22867 · Cited by 465
Self-citationKaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., Olivo, M. S., He, Y., Dutcus, C. E., & Cortes, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4892 · Cited by 463
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434
Untch, M., Jackisch, C., Schneeweiss, A., Conrad, B., Aktas, B., Denkert, C., Eidtmann, H., Wiebringhaus, H., Kümmel, S., Hilfrich, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00542-2 · Cited by 414
A brief history of the opioid epidemic and strategies for pain medicine
Jones, M. R., Viswanath, O., Peck, J., Kaye, A. D., Gill, J. S., & Simopoulos, T. T. (2018) · Pain and Therapy · doi:10.1007/s40122-018-0097-6 · Cited by 405
André, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., Lacroix-Triki, M., Lacroix, L., Cohen, P., Gentien, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70611-9 · Cited by 404
Self-citationPaluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw327 · Cited by 399
Self-citationEnzinger, A. C., Zhang, B., Schrag, D., & Prigerson, H. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.9239 · Cited by 379
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Livingston, R. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201622 · Cited by 371
When the treatment goal is not cure: are cancer patients equipped to make informed decisions?
Gattellari, M., Voigt, K. J., Butow, P. N., & Tattersall, M. H. N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.2.503 · Cited by 344
Increased Risk of Recurrence After Hormone Replacement Therapy in Breast Cancer Survivors
Holmberg, L., Iversen, O.-E., Rudenstam, C. M., Hammar, M., Kumpulainen, E., Jaskiewicz, J., Jassem, J., Dobaczewska, D., Fjosne, H. E., Peralta, O., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn058 · Cited by 344
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.08.009 · Cited by 338
Self-citationGlobal analysis of advanced/metastatic breast cancer: decade report (2005-2015)
Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J., Cardoso, M.-J., Peccatori, F., Paonessa, D., Benares, A., et al. (2018) · The Breast · doi:10.1016/j.breast.2018.03.002 · Cited by 324
Self-citationMann, E., Smith, M. J., Hellier, J., Balabanovic, J. A., Hamed, H., Grunfeld, E. A., & Hunter, M. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70364-3 · Cited by 307
1st International consensus guidelines for advanced breast cancer (ABC 1)
Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., et al. (2012) · The Breast · doi:10.1016/j.breast.2012.03.003 · Cited by 303
Self-citationFried, T. R., Bradley, E. H., & O'Leary, J. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51457.x · Cited by 301
Peterson, D. E., Boers-Doets, C. B., Bensadoun, R. J., & Herrstedt, J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv202 · Cited by 299
A Comprehensive Definition for Integrative Oncology
Witt, C. M., Balneaves, L. G., Cardoso, M. J., Cohen, L., Greenlee, H., Johnstone, P., Kücük, Ö., Mailman, J., & Mao, J. J. (2017) · JNCI Monographs · doi:10.1093/jncimonographs/lgx012 · Cited by 296
Self-citation進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar, L. B., Barrios, C. H., van den Bergh, J. P., et al. (2018) · Annals of Oncology · Cited by 296
Self-citationAndersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., Karlsson, P., Tange, U. B., Sørensen, P. G., Møller, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8213 · Cited by 294
Self-citationIwamoto, T., Booser, D., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., Ueno, N. T., Zhang, J., Shi, W., Qi, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2574 · Cited by 288
Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Physical activity for women with breast cancer after adjuvant therapy
Lahart, I. M., Metsios, G. S., Nevill, A. M., & Carmichael, A. R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011292.pub2 · Cited by 282
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Gobbini, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., Dalenc, F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.015 · Cited by 276
Self-citationThompson, A. M., Jordan, L. B., Quinlan, P., Anderson, E., Skene, A., Dewar, J. A., Purdie, C. A., & the Breast Recurrence in Tissues Study Group (2010) · Breast Cancer Research · doi:10.1186/bcr2771 · Cited by 253
Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M., Iwata, H., Harbeck, N., Cristofanilli, M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0097 · Cited by 249
Self-citationWhich threshold for ER positivity? a retrospective study based on 9639 patients
Yi, M., Huo, L., Koenig, K. B., Mittendorf, E. A., Meric-Bernstam, F., Kuerer, H. M., Bedrosian, I., Buzdar, A. U., Symmans, W. F., Crow, J. R., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu053 · Cited by 243
Pivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242
Travier, N., Velthuis, M. J., Steins Bisschop, C. N., van den Buijs, B., Monninkhof, E. M., Backx, F., Los, M., Erdkamp, F., Bloemendal, H. J., Rodenhuis, C., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0362-z · Cited by 240
Rugo, H. S., Seneviratne, L., Beck, J. T., Glaspy, J. A., Peguero, J. A., Pluard, T. J., Dhillon, N., Hwang, L. C., Nangia, C., Mayer, I. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30109-2 · Cited by 226
Self-citationDuijts, S. F. A., van Beurden, M., Oldenburg, H. S. A., Hunter, M. S., Kieffer, J. M., Stuiver, M. M., Gerritsma, M. A., Menke-Pluymers, M. B. E., Plaisier, P. W., Rijna, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8525 · Cited by 220
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy014 · Cited by 215
Self-citationBurstein, H. J., Keshaviah, A., Baron, A. D., Hart, R. D., Lambert‐Falls, R., Marcom, P. K., Gelman, R., & Winer, E. P. (2007) · Cancer · doi:10.1002/cncr.22885 · Cited by 214
Self-citationAmadori, D., Aglietta, M., Alessi, B., Gianni, L., Ibrahim, T., Farina, G., Gaion, F., Bertoldo, F., Santini, D., Rondena, R., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70174-8 · Cited by 203
Berger, A. M., Mitchell, S. A., Jacobsen, P. B., & Pirl, W. F. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21268 · Cited by 196
Liedtke, C., Thill, M., & on behalf of the AGO Breast Committee (2016) · Breast Care · doi:10.1159/000446941 · Cited by 189
Hartman, S. J., Nelson, S. H., Myers, E., Natarajan, L., Sears, D. D., Palmer, B. W., Weiner, L. S., Parker, B. A., & Patterson, R. E. (2018) · Cancer · doi:10.1002/cncr.30987 · Cited by 188
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis
Torcuator, R., Zuniga, R., Mohan, Y. S., Rock, J., Doyle, T., Anderson, J., Gutierrez, J., Ryu, S., Jain, R., Rosenblum, M., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9801-z · Cited by 188
Improved survival in metastatic breast cancer 1985-2016
Sundquist, M., Brudin, L., & Tejler, G. (2017) · The Breast · doi:10.1016/j.breast.2016.10.005 · Cited by 188
Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011
Thomas, A., Khan, S. A., Chrischilles, E. A., & Schroeder, M. C. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2015.4539 · Cited by 176 · cited 1×
“Until then, the recommendation is to discuss surgery on a case-by-case basis and importantly, only consider surgery if it can be performed with a high quality procedure [21].”
Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw139 · Cited by 176
Self-citationTutt, A., Ellis, P., Kilburn, L., Gilett, C., Pinder, S., Abraham, J., Barrett, S., Barrett-Lee, P., Chan, S., Cheang, M., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s3-01 · Cited by 167
Self-citationRugo, H. S., Dieras, V. C., Gelmon, K. A., Finn, R. S., Slamon, D. J., Martín, M., Neven, P., Shparyk, Y. V., Mori, A., Lu, D. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy012 · Cited by 160
Self-citationHormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial
Fahlén, M., Fornander, T., Johansson, H., Johansson, U., Rutqvist, L.-E., Wilking, N., & von Schoultz, E. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.07.003 · Cited by 158
Melisko, M. E., Goldman, M. E., Hwang, J., De Luca, A., Fang, S., Esserman, L. J., Chien, A. J., Park, J. W., & Rugo, H. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3904 · Cited by 155
Self-citation(2010) · PubMed · Cited by 151
Effect of ASCO/CAP guidelines for determining ER status on molecular subtype
Deyarmin, B., Kane, J. L., Valente, A. L., van Laar, R., Gallagher, C., Shriver, C. D., & Ellsworth, R. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2588-8 · Cited by 149
Clinical overview of metronomic chemotherapy in breast cancer
Munzone, E., & Colleoni, M. A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.131 · Cited by 147
Malmgren, J. A., Mayer, M., Atwood, M. K., & Kaplan, H. G. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4529-5 · Cited by 147
Self-citationManagement of fatigue in patients with cancer – A practical overview
Koornstra, R. H. T., Peters, M. E. W. J., Donofrio, S. M., van den Borne, B., & de Jong, F. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.01.004 · Cited by 131
Chen, W. Y., Giobbie-Hurder, A., Gantman, K., Savoie, J., Scheib, R., Parker, L. M., & Schernhammer, E. S. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2944-4 · Cited by 130
What do advanced cancer patients know of their disease?: A report from Italy
Pronzato, P., Bertelli, G., Losardo, P., & Landucci, M. (1994) · Supportive Care in Cancer · doi:10.1007/bf00365729 · Cited by 124
Pritchard, K. I., Burris, H. A., Ito, Y., Rugo, H. S., Dakhil, S. R., Hortobágyi, G. N., Campone, M., Csőszi, T., Baselga, J. M., Puttawibul, P., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.08.011 · Cited by 112
Self-citationThe effect of melatonin on sleep and quality of life in patients with advanced breast cancer
Innominato, P. F., Lim, A. S., Palesh, O., Clemons, M., Trudeau, M., Eisen, A., Wang, C., Kiss, A., Pritchard, K. I., & Bjarnason, G. A. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-015-2883-6 · Cited by 111
Finn, R. S., Martín, M., Rugo, H. S., Jones, S. E., Im, S., Gelmon, K. A., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.507 · Cited by 109
Self-citationBarnett, M. M. (2006) · Psycho-Oncology · doi:10.1002/pon.921 · Cited by 102
Verma, S., O’Shaughnessy, J., Burris, H. A., Campone, M., Alba, E., Chandiwana, D., Dalal, A. A., Sutradhar, S., Monaco, M., & Janni, W. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4769-z · Cited by 100
An analysis of radiation necrosis of the central nervous system treated with bevacizumab
Tye, K. E., Engelhard, H. H., Slavin, K. V., Nicholas, M. K., Chmura, S. J., Kwok, Y., Ho, D. S., Weichselbaum, R. R., & Koshy, M. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1391-8 · Cited by 99
Delishaj, D., Ursino, S., Pasqualetti, F., Cristaudo, A., Cosottini, M., Fabrini, M. G., & Paiar, F. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2936e · Cited by 94
Chen, T., Zhang, N., Moran, M. S., Su, P., Haffty, B. G., & Yang, Q. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.06.005 · Cited by 94
Committee Opinion No. 659 Summary
(2016) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001349 · Cited by 91
Bartula, I., & Sherman, K. A. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2623-y · Cited by 87
Hersant, B., SidAhmed-Mezi, M., Belkacemi, Y., Darmon, F., Bastuji-Garin, S., Werkoff, G., Bosc, R., Niddam, J., Hermeziu, O., La Padula, S., et al. (2018) · Menopause · doi:10.1097/gme.0000000000001122 · Cited by 86
Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma.
Weigel, R. J., & deConinck, E. C. (1993) · PubMed · Cited by 83
Lobbezoo, D. J. A., van Kampen, R. J. W., Voogd, A. C., Dercksen, M. W., van den Berkmortel, F. W. P. J., Smilde, T. J., van de Wouw, A. J., Peters, F. P. J., van Riel, J., Peters, N. A. J. B., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv544 · Cited by 82
Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression
Balduzzi, A., Bagnardi, V., Rotmensz, N., Dellapasqua, S., Montagna, E., Cardillo, A., Viale, G., Veronesi, P., Intra, M., Luini, A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.019 · Cited by 80
European Breast Cancer Conference manifesto on breast centres/units
Cardoso, F., Cataliotti, L., Costa, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.023 · Cited by 79
Self-citationStockler, M. R., Tattersall, M. H. N., Boyer, M. J., Clarke, S. J., Beale, P. J., & Simes, R. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602908 · Cited by 77
Kiely, B. E., McCaughan, G., Christodoulou, S., Beale, P. J., Grimison, P., Trotman, J., Tattersall, M. H. N., & Stockler, M. R. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-012-1526-4 · Cited by 76
Gómez, P., & Lacouture, M. E. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0115 · Cited by 73
Johns, C., Seav, S. M., Dominick, S. A., Gorman, J. R., Li, H., Natarajan, L., Mao, J. J., & Irene Su, H. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3765-4 · Cited by 72
Royce, M., Bachelot, T., Villanueva, C., Özgüroğlu, M., Azevedo, S. J., Cruz, F. M., Debled, M., Hegg, R., Toyama, T., Falkson, C. I., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0060 · Cited by 71
Self-citationReversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients
Wang, Y., Pan, L., Sheng, X., Mao, Y. Q., Yao, Y., Wang, E., Zhang, N., & Dai, J. (2012) · European journal of medical research · doi:10.1186/2047-783x-17-25 · Cited by 68
Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., & Marschner, N. (2017) · The Breast · doi:10.1016/j.breast.2017.05.014 · Cited by 65
Caruso, S., Cianci, S., Amore, F. F., Ventura, B., Bambili, E., Spadola, S., & Cianci, A. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000485 · Cited by 64
Gloyeske, N. C., Dabbs, D. J., & Bhargava, R. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcp34cysatwfdpq · Cited by 63
Kiely, B. E., Martin, A. J., Tattersall, M. H. N., Nowak, A. K., Goldstein, D., Wilcken, N. R. C., Wyld, D. K., Abdi, E. A., Glasgow, A., Beale, P. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7821 · Cited by 62
Cardoso, F., Harbeck, N., Mertz, S. A., & Fenech, D. (2016) · The Breast · doi:10.1016/j.breast.2016.04.004 · Cited by 61
Self-citationHortobágyi, G. N., Stemmer, S. M., Burris, H. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1038 · Cited by 55
A Practical Approach to Fatigue Management in Colorectal Cancer
Aapro, M., Scotte, F., Bouillet, T., Currow, D., & Vigano, A. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.04.010 · Cited by 54
Self-citationTolaney, S. M., Lin, N., Thornton, D., Klise, S. R., Costigan, T. M., Turner, P. K., & Anders, C. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1019 · Cited by 54
Karlsson, E., Appelgren, J., Solterbeck, A., Bergenheim, M., Alvariza, V., & Bergh, J. C. S. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.08.014 · Cited by 53
Self-citationHölzel, D., Eckel, R., Bauerfeind, I., Baier, B., Beck, T., Braun, M., Ettl, J., Hamann, U., Kiechle, M. B., Mahner, S., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2428-0 · Cited by 52
Self-citationRamaswami, R., Villarreal, M. D., Pitta, D. M., Carpenter, J. S., Stebbing, J., & Kalesan, B. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3465-5 · Cited by 49
Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
Stute, P. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-3068-5 · Cited by 49
Kobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., Takahashi, S., Akiyama, F., Iwase, T., Hozumi, Y., Yasuda, Y., et al. (2016) · Surgery Today · doi:10.1007/s00595-015-1252-x · Cited by 45 · cited 1×
“Some more recent series seem to indicate an improvement in median overall survival [5, 6].”
Donders, G. G. G., Bellen, G., Neven, P., Grob, P., Prasauskas, V., Buchholz, S., & Ortmann, O. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2447-1 · Cited by 45
Vaginal estriol–lactobacilli combination and quality of life in endocrine-treated breast cancer
Buchholz, S., Mögele, M., Lintermans, A., Bellen, G., Prasauskas, V., Ortmann, O., Grob, P., Neven, P., & Donders, G. G. G. (2014) · Climacteric · doi:10.3109/13697137.2014.991301 · Cited by 45
Noguchi, S., Kim, H. J., Anita, J., Parmar, V. V., Sato, N., Wang, H.-C., Lokejaroenlarb, S., Isidro, J., Kim, K. S., Itoh, Y., et al. (2015) · Breast Cancer · doi:10.1007/s12282-015-0637-4 · Cited by 43
Witt, C. M., & Cardoso, M. J. (2016) · The Breast · doi:10.1016/j.breast.2016.04.012 · Cited by 42
Self-citationMazzarello, S., Hutton, B., Ibrahim, M. F. K., Jacobs, C. M., Shorr, R., Smith, S. R., Ng, T. L., & Clemons, M. J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3434-z · Cited by 41
Smyth, L. M., Iyengar, N. M., Chen, M. F., Popper, S. M., Patil, S. N., Wasserheit-Lieblich, C., Argolo, D. F. S. D. T. E., Singh, J. C., Chandarlapaty, S., Sugarman, S. M., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3851-7 · Cited by 39
Self-citationFallowfield's Sexual Activity Questionnaire in women with without and at risk of cancer
Atkins, L., & Fallowfield, L. J. (2007) · Menopause international · doi:10.1258/175404507781605578 · Cited by 36
Self-citationHortobágyi, G. N., Lipton, A., Chew, H. K., Gradishar, W. J., Sauter, N. P., Mohanlal, R. W., Zheng, M., McGrain, B., & Poznak, C. H. V. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba9500 · Cited by 36
Stefanopoulou, E., & Grunfeld, E. A. (2017) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2016.1235147 · Cited by 35
Cross-cultural differences in information disclosure evaluated through the EORTC questionnaires
Arraras, J. I., Greimel, E., Chie, W., Sezer, O., Bergenmar, M., Costantini, A., Young, T., Vlasic, K. K., Velikova, G., & on behalf of the European Organisation for Research and Treatment of Cancer Quality of Life Group (2013) · Psycho-Oncology · doi:10.1002/pon.2088 · Cited by 34
Origoni, M., Cimmino, C., Carminati, G., Iachini, E., Stefani, C., Girardelli, S., Salvatore, S., & Candiani, M. (2016) · PubMed · Cited by 32
Tripathy, D., Sohn, J., Im, S., Colleoni, M. A., Franke, F. A., Bardia, A., Harbeck, N., Hurvitz, S., Chow, L. W. C., Lee, K., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-gs2-05 · Cited by 32
Self-citationTripathy, D., Rugo, H. S., Kaufman, P. A., Swain, S. M., O’Shaughnessy, J., Jahanzeb, M., Mason, G., Beattie, M. S., Yoo, B., Lai, C., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-307 · Cited by 28
Self-citationFallowfield, L. J., Catt, S. L., May, S. F., Matthews, L., Shilling, V. M., Simcock, R., Westwell, S., & Jenkins, V. A. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-016-3408-7 · Cited by 25
Self-citationSerati, M., Bogani, G., Dedda, M. C. D., et al. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.05.026 · Cited by 23
Penault-Llorca, F. M., Coudry, R. A., Hanna, W. M., OSAMURA, R. Y., Rüschoff, J., & Viale, G. (2013) · The Breast · doi:10.1016/j.breast.2012.12.004 · Cited by 23
Self-citationMONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer
Leo, A. D., Toi, M., Campone, M., Sohn, J., Paluch–Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.008 · Cited by 20
Genetic testing in women with breast cancer: implications for treatment
Paterson, R. J., & Phillips, K. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1374175 · Cited by 19
Goetz, M. P., Toi, M., Klise, S. R., Frenzel, M., Bourayou, N., & Leo, A. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps624 · Cited by 16
Verma, S., O’Shaughnessy, J., Burris, H. A., Campone, M., Alba, E., Chandiwana, D., Manson, S. C., Sutradhar, S., Monaco, M., & Janni, W. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1020 · Cited by 16
453 Trends in survival in metastatic breast cancer
Sundquist, M., Eriksson, Z., Brudin, L. H., & Tejler, G. (2010) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(10)70474-2 · Cited by 12
INTERVENTIONS FOR FATIGUE AND WEIGHT LOSS IN ADULTS WITH ADVANCED PROGRESSIVE ILLNESS
(2012) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2012.687944 · Cited by 11
Editorial: Why are guidelines not followed in clinical practice?
Cardoso, F., & Gennari, A. (2016) · The Breast · doi:10.1016/j.breast.2016.12.004 · Cited by 6
Self-citationHarbeck, N., Iyer, S. S., Bhattacharyya, H., et al. (2017) · The Breast · doi:10.1016/s0960-9776(17)30684-7 · Cited by 5
Self-citation
Research works printed but not linked: 12
- Howlader, 2016, SEER Cancer Statistics Review, 1975–2013
- Schrijver, 2016, Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer, Mod Pathol, 10.1038/modpathol.2016.116 · doi:10.1038/modpathol.2016.116
- Soran, 2016, A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01), J Clin Oncol, 34
- Ellis, 2015, Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study, J Clin Oncol, 33
- Urruticoechea, 2016, PHEREXA: a phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting, J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.504 · doi:10.1200/jco.2016.34.15_suppl.504
- Rayson, 2014, Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact, Breast J, 20, 408, 10.1111/tbj.12284 · doi:10.1111/tbj.12284
- Andersson, 2015, The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis, J Clin Oncol, 33, 586., 10.1200/jco.2015.33.15_suppl.586 · doi:10.1200/jco.2015.33.15_suppl.586
- Tutt, 2015, TNT: a randomized phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer, Cancer Res, 75, S3
- Cortes, 2015, Overall survival (OS) from the phase 2 study of enzalutamide, an androgen receptor (AR) signaling inhibitor, in ar+ advanced triple-negative breast cancer (aTNBC), Eur J Cancer, 51
- Himelstein, 2015, CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.9501 · doi:10.1200/jco.2015.33.15_suppl.9501
- VEJonesLLJensenKJMcIntyre. Evaluation of miracle mouthwash (MMW) plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: preliminary results of a randomized phase II study. 2015 San Antonio Breast Cancer Symposium; December 5–8, 2015; San Antonio, TX. Abstract P1-15-06. · doi:10.1158/1538-7445.sabcs15-p1-15-06
- Rugo, 2016, Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): results of the SWISH trial, J Clin Oncol, 34, 10.1200/jco.2016.34.26_suppl.189 · doi:10.1200/jco.2016.34.26_suppl.189
Cited by
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Self-citationSacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Self-citationGennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Self-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
Self-citation
Metadata
- Authors
- Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M. J., Pierga, J. Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., & Winer, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 28
- Issue
- 1
- Pages
- 16-33
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2560635244
- Cited by
- 2,033
- References
- 167
- FWCI
- 62.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1037 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.